ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists' training.


Journal

European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 19 02 2020
accepted: 29 04 2020
revised: 01 04 2020
pubmed: 20 5 2020
medline: 11 2 2021
entrez: 20 5 2020
Statut: ppublish

Résumé

This study aims to define consensus-based criteria for acquiring and reporting prostate MRI and establishing prerequisites for image quality. A total of 44 leading urologists and urogenital radiologists who are experts in prostate cancer imaging from the European Society of Urogenital Radiology (ESUR) and EAU Section of Urologic Imaging (ESUI) participated in a Delphi consensus process. Panellists completed two rounds of questionnaires with 55 items under three headings: image quality assessment, interpretation and reporting, and radiologists' experience plus training centres. Of 55 questions, 31 were rated for agreement on a 9-point scale, and 24 were multiple-choice or open. For agreement items, there was consensus agreement with an agreement ≥ 70% (score 7-9) and disagreement of ≤ 15% of the panellists. For the other questions, a consensus was considered with ≥ 50% of votes. Twenty-four out of 31 of agreement items and 11/16 of other questions reached consensus. Agreement statements were (1) reporting of image quality should be performed and implemented into clinical practice; (2) for interpretation performance, radiologists should use self-performance tests with histopathology feedback, compare their interpretation with expert-reading and use external performance assessments; and (3) radiologists must attend theoretical and hands-on courses before interpreting prostate MRI. Limitations are that the results are expert opinions and not based on systematic reviews or meta-analyses. There was no consensus on outcomes statements of prostate MRI assessment as quality marker. An ESUR and ESUI expert panel showed high agreement (74%) on issues improving prostate MRI quality. Checking and reporting of image quality are mandatory. Prostate radiologists should attend theoretical and hands-on courses, followed by supervised education, and must perform regular performance assessments. • Multi-parametric MRI in the diagnostic pathway of prostate cancer has a well-established upfront role in the recently updated European Association of Urology guideline and American Urological Association recommendations. • Suboptimal image acquisition and reporting at an individual level will result in clinicians losing confidence in the technique and returning to the (non-MRI) systematic biopsy pathway. Therefore, it is crucial to establish quality criteria for the acquisition and reporting of mpMRI. • To ensure high-quality prostate MRI, experts consider checking and reporting of image quality mandatory. Prostate radiologists must attend theoretical and hands-on courses, followed by supervised education, and must perform regular self- and external performance assessments.

Identifiants

pubmed: 32424596
doi: 10.1007/s00330-020-06929-z
pii: 10.1007/s00330-020-06929-z
pmc: PMC7476997
doi:

Types de publication

Consensus Development Conference Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5404-5416

Subventions

Organisme : Wellcome Trust
ID : 204998/Z/16/Z
Pays : United Kingdom

Références

Eur Urol. 2019 Nov;76(5):574-581
pubmed: 31167748
Eur Urol. 2019 Nov;76(5):584-585
pubmed: 31409496
Eur Urol. 2020 Jan;77(1):78-94
pubmed: 31326219
N Engl J Med. 2018 May 10;378(19):1767-1777
pubmed: 29552975
Eur Urol. 2019 Sep;76(3):284-303
pubmed: 31130434
Abdom Radiol (NY). 2019 May;44(5):1883-1893
pubmed: 30788558
BJU Int. 2018 Jul;122(1):13-25
pubmed: 29699001
J Magn Reson Imaging. 2017 Feb;45(2):579-585
pubmed: 27391860
Clin Radiol. 2019 Nov;74(11):894.e19-894.e25
pubmed: 31296337
AJR Am J Roentgenol. 2017 Mar;208(3):W92-W100
pubmed: 28026201
J Urol. 2020 Apr;203(4):706-712
pubmed: 31642740
Eur Urol. 2019 Apr;75(4):570-578
pubmed: 30477981
BJU Int. 2016 Jan;117(1):80-6
pubmed: 25099182
Curr Probl Diagn Radiol. 2019 Mar - Apr;48(2):132-141
pubmed: 29428182
Lancet. 2017 Feb 25;389(10071):815-822
pubmed: 28110982
J Magn Reson Imaging. 2019 Feb;49(2):546-555
pubmed: 30187600
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
Eur Urol. 2020 Apr;77(4):457-468
pubmed: 31582290
Eur Radiol. 2017 Jun;27(6):2259-2266
pubmed: 27778089
Lancet Oncol. 2019 Jan;20(1):100-109
pubmed: 30470502
Eur Urol. 2017 Aug;72(2):250-266
pubmed: 28336078
AJR Am J Roentgenol. 2019 Mar 27;:1-8
pubmed: 30917023
Acad Radiol. 2018 Feb;25(2):188-195
pubmed: 29107458
Eur Urol. 2019 Sep;76(3):340-351
pubmed: 30898406
Am Health Drug Benefits. 2016 Feb;9(1):42-50
pubmed: 27066195
Abdom Imaging. 2015 Jan;40(1):134-42
pubmed: 25034558
Clin Radiol. 2019 Nov;74(11):894.e1-894.e9
pubmed: 31288924
Eur Urol. 2018 Jul;74(1):48-54
pubmed: 29566957
Curr Opin Urol. 2015 Nov;25(6):522-35
pubmed: 26375060

Auteurs

Maarten de Rooij (M)

Department of Radiology & Nuclear Medicine and Anatomy, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands. Maarten.derooij@radboudumc.nl.

Bas Israël (B)

Department of Radiology & Nuclear Medicine and Anatomy, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
Department of Urology and Department of Radiology & Nuclear Medicine, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.

Marcia Tummers (M)

Department for Health Evidence, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.

Hashim U Ahmed (HU)

Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.
Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.

Tristan Barrett (T)

Department of Radiology, CamPARI Prostate Cancer Group, Addenbrooke's Hospital and University of Cambridge, Cambridge, UK.

Francesco Giganti (F)

Department of Radiology, University College London Hospital NHS Foundation Trust, London, UK.
Division of Surgery & Interventional Science, University College London, London, UK.

Bernd Hamm (B)

Department of Radiology, Charité, Berlin, Germany.

Vibeke Løgager (V)

Department of Radiology, Herlev Gentofte University Hospital, Herlev, Denmark.

Anwar Padhani (A)

Paul Strickland Scanner Centre, Mount Vernon Cancer Centre, Northwood, UK.

Valeria Panebianco (V)

Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Rome, Italy.

Philippe Puech (P)

Department of Radiology, University of Lille, Lille, France.

Jonathan Richenberg (J)

Department of Imaging, Brighton and Sussex University Hospital NHS Trust, Brighton, UK.

Olivier Rouvière (O)

Department of Urinary and Vascular Radiology, Hôpital Édouard-Herriot, Lyon, France.
Faculté de Médecine Lyon Est, Université Lyon 1, Lyon, France.

Georg Salomon (G)

Martini Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Ivo Schoots (I)

Department of Radiology & Nuclear Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Jeroen Veltman (J)

Department of Radiology, Ziekenhuisgroep Twente, Almelo, The Netherlands.

Geert Villeirs (G)

Department of Radiology, Ghent University Hospital, Ghent, Belgium.

Jochen Walz (J)

Department of Urology, Institute Paoli-Calmettes Cancer Center, Marseille, France.

Jelle O Barentsz (JO)

Department of Radiology & Nuclear Medicine and Anatomy, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH